Oncology
Congress Materials – Western Section American Urology Association (WSAUA 2025)
2025 Western Section American Urology Association | Nov 2-6 | Napa, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Matching-Adjusted Indirect Comparisons of TAR-200 vs. FDA-Approved Novel Agents in Bacillus Calmette-Guérin-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer with Carcinoma in Situ
Siamak Daneshmand, Sarah Côté, Ruhee Jain, Xiwu Lin, Jianming He, Hussein Sweiti, Shalaka Hampras, Félix Guerrero-Ramos
Nurse and Advanced Practice Provider Perspectives on Gemcitabine Intravesical System Treatment of High-Risk Non–Muscle-Invasive Bladder Cancer in the Urology Clinic
Siamak Daneshmand, Kristen Crowley, Nicole Osimo, Cheryl Zinar, Laurence H. Belkoff, Hussein Sweiti, Jason Martin, Shalaka Hampras
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.